Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Eron, J.J.; Orkin, C.; Cunningham, D.; Pulido, F.; Post, F.A.; De Wit, S.; Lathouwers, E.; Hufkens, V.; Jezorwski, J.; Petrovic, R.; Brown, K.; Van Landuyt, E.; Opsomer, M.; De Wit, S.; Florence, E.; Moutschen, M.; Van Wijngaerden, E.; Vandekerckhove, L.; Vandercam, B.; Brunetta, J.; Conway, B.; Klein, M.; Murphy, D.; Rachlis, A.; Shafran, S.; Walmsley, S.; Ajana, F.; Cotte, L.; Girardy, P.-M.; Katlama, C.; Molina, J.-M.; Poizot-Martin, I.; Raffi, F.; Rey, D.; Reynes, J.; Teicher, E.; Yazdanpanah, Y.; Gasiorowski, J.; Halota, W.; Horban, A.; Piekarska, A.; Witor, A.; Arribas, J.R.; Perez-Valero, I.; Berenguer, J.; Casado, J.; Gatell, J.M.; Gutierrez, F.; Galindo, M.J.; Gutierrez, M.D.M.; Iribarren, J.A.; Knobel, H.; Negredo, E.; Pineda, J.A.; Podzamczer, D.; Sogorb, J.P.; Pulido, F.; Ricart, C.; Rivero, A.; Santos Gil, I.; Blaxhult, A.; Flamholc, L.; Gisslèn, M.; Thalme, A.; Fehr, J.; Rauch, A.; Stoeckle, M.; Clarke, A.; Gazzard, B.G.; Johnson, M.A.; Orkin, C.; Ustianowski, A.; Waters, L.; Bailey, J.; Benson, P.; Bhatti, L.; Brar, I.; Bredeek, U.F.; Brinson, C.; Crofoot, G.; Cunningham, D.; DeJesus, E.; Dietz, C.; Dretler, R.; Eron, J.; Felizarta, F.; Fichtenbaum, C.; Gallant, J.; Gathe, J.; Hagins, D.; Henn, S.; Henry, W.K.; Huhn, G.; Jain, M.; Lucasti, C.; Martorell, C.; McDonald, C.; Mills, A.; Morales-Ramirez, J.; Mounzer, K.; Nahass, R.; Olivet, H.; Osiyemi, O.; Prelutsky, D.; Ramgopal, M.; Rashbaum, B.; Richmond, G.; Ruane, P.; Scarsella, A.; Scribner, A.; Shalit, P.; Shamblaw, D.; Slim, J.; Tashima, K.; Voskuhl, G.; Ward, D.; Wilkin, A.; de Vente, J.

doi:10.1016/J.ANTIVIRAL.2019.104543

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Eron, J.J.
Orkin, C.
Cunningham, D.
Pulido, F.
Post, F.A.
De Wit, S.
Lathouwers, E.
Hufkens, V.
Jezorwski, J.
Petrovic, R.
Brown, K.
Van Landuyt, E.
Opsomer, M.
De Wit, S.
Florence, E.
Moutschen, M.
Van Wijngaerden, E.
Vandekerckhove, L.
Vandercam, B.
Brunetta, J.
Conway, B.
Klein, M.
Murphy, D.
Rachlis, A.
Shafran, S.
Walmsley, S.
Ajana, F.
Cotte, L.
Girardy, P.-M.
Katlama, C.
Molina, J.-M.
Poizot-Martin, I.
Raffi, F.
Rey, D.
Reynes, J.
Teicher, E.
Yazdanpanah, Y.
Gasiorowski, J.
Halota, W.
Horban, A.
Piekarska, A.
Witor, A.
Arribas, J.R.
Perez-Valero, I.
Berenguer, J.
Casado, J.
Gatell, J.M.
Gutierrez, F.
Galindo, M.J.
Gutierrez, M.D.M.
Iribarren, J.A.
Knobel, H.
Negredo, E.
Pineda, J.A.
Podzamczer, D.
Sogorb, J.P.
Pulido, F.
Ricart, C.
Rivero, A.
Santos Gil, I.
Blaxhult, A.
Flamholc, L.
Gisslèn, M.
Thalme, A.
Fehr, J.
Rauch, A.
Stoeckle, M.
Clarke, A.
Gazzard, B.G.
Johnson, M.A.
Orkin, C.
Ustianowski, A.
Waters, L.
Bailey, J.
Benson, P.
Bhatti, L.
Brar, I.
Bredeek, U.F.
Brinson, C.
Crofoot, G.
Cunningham, D.
DeJesus, E.
Dietz, C.
Dretler, R.
Eron, J.
Felizarta, F.
Fichtenbaum, C.
Gallant, J.
Gathe, J.
Hagins, D.
Henn, S.
Henry, W.K.
Huhn, G.
Jain, M.
Lucasti, C.
Martorell, C.
McDonald, C.
Mills, A.
Morales-Ramirez, J.
Mounzer, K.
Nahass, R.
Olivet, H.
Osiyemi, O.
Prelutsky, D.
Ramgopal, M.
Rashbaum, B.
Richmond, G.
Ruane, P.
Scarsella, A.
Scribner, A.
Shalit, P.
Shamblaw, D.
Slim, J.
Tashima, K.
Voskuhl, G.
Ward, D.
Wilkin, A.
de Vente, J.
Show all authors +

Journal:

Antiviral Research

ISSN: 1872-9096, 0166-3542

Year of publication: 2019

Volume: 170

Type: Article

DOI: 10.1016/J.ANTIVIRAL.2019.104543 GOOGLE SCHOLAR Open access editor

Data source: Scopus